

Chiral Bronsted Acid-Catalyzed Stereoselective Mannich-type Reaction of Azlactones with Aldimines

Eloah P Ávila, Rodrigo M. S. Justo, Vanessa P Gonçalves, Adriane A. Pereira, Renata Diniz, and Giovanni W Amarante

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/jo5024975 • Publication Date (Web): 03 Dec 2014

Downloaded from <http://pubs.acs.org> on December 11, 2014

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.



Chiral Brønsted Acid-Catalyzed Stereoselective Mannich-type Reaction of Azlactones with Aldimines[‡]


Eloah P. Ávila, Rodrigo M. S. Justo, Vanessa P. Gonçalves, Adriane A. Pereira,
Renata Diniz and Giovanni W. Amarante*

*Chemistry Department, Federal University of Juiz de Fora, Cidade Universitária
Martelos, Martelos, Juiz de Fora / MG / Brazil / CEP: 36036-900*

corresponding author: giovanni.amarante@ufjf.edu.br

[‡]Dedicated to Professor Fernando Coelho in recognition of his outstanding contributions to
Brazilian chemistry.

TOC graphic



Abstract

A highly diastereo- and enantioselective Mannich-type reaction of azlactones with aldimines catalyzed by a chiral phosphoric acid is described. Only 3 mol% of the catalyst was required to prepare the Mannich adducts in good yields with high stereochemical control (up to > 19:1 dr, > 99:1 er). Moreover, the final

1
2
3 product contains two consecutive stereogenic centers, one of which is
4
5 quaternary.
6

7
8 **Keywords:** azlactones; aldimines; Mannich-type reaction; asymmetric
9
10 organocatalysis; chiral phosphoric acid.
11


12
13 Chiral α,β -diaminoacid derivatives are very important building blocks in organic
14
15 chemistry as they possess remarkable pharmacological properties. Viso and co-
16
17 workers have showed the importance of these motifs in treatment of
18
19 neurodegenerative diseases and various cancers. [1] A variety of methods for
20
21 the synthesis chiral α,β -diaminoacid derivatives have been reported. [1] One
22
23 attractive route utilizes azlactones; as these rings are essentially protected
24
25 aminoacids that are readily unmasked under acidic conditions. Additionally,
26
27 azlactones can be easily prepared on preparative scale following literature
28
29 protocols and derivatized through [2] Mannich-type reaction [3] mediated by
30
31 transition metals or organocatalysts [4], [5].
32
33
34
35

36
37 In particular, chiral gold(I) complexes have been used to catalyze the
38
39 enantioselective Mannich reaction of azlactones. Reaction of aliphatic
40
41 mesitylsulfonimines with azlactones in the presence of a spirocyclic
42
43 bisphosphine gold(I) benzoate complex (xylyl-SDP(AuOBz)₂), provided the
44
45 desired 1,2-*anti*-Mannich adducts in high yields and selectivities. [4] In contrast,
46
47 organocatalytic approaches tolerate both aromatic and aliphatic imines for
48
49 synthesis of chiral α,β -diaminoacid derivatives in high yields and selectivities.
50
51 [5a], [5b]. Interestingly, the major product observed in these reactions were the
52
53 1,2-*syn* diastereomers.
54
55
56
57
58
59
60

1
2
3 Since the pioneering work of Terada [6] and Akiyama [7] which demonstrated
4 the potential of chiral phosphoric acids as organocatalysts, new applications
5 exploiting the H-donor capacity of these catalysts have appeared in the
6 literature. [8] In our research program [9], we envisioned that chiral phosphoric
7 acids could be an alternative, metal-free catalyst for the reaction between
8 azlactones and aldimines. Moreover, we envisioned that this approach may be
9 complementary to existing organocatalytic methods and provide access to the
10 1,2-*anti*-diaminoacid derivatives from aromatic imines.
11
12
13
14
15
16
17
18
19

20
21 The azlactone and imine skeletons are both readily accessed following literature
22 protocols. [4] To our delight, the reaction between azlactone **1a** and aldimine **2a**
23 catalyzed by only 3 mol% of the commercial available (*S*)-3,3'-Bis(2,4,6-
24 triisopropylphenyl)-1,1'-binaphthyl-2,2'-diyl hydrogenphosphate, (*S*)-TRIP [10],
25 in toluene gave the desired Mannich adduct **3a** in good yield (70 %; isolated
26 yield) and excellent enantio- and diastereoselectivity (Table 1, entry 3).
27
28 However, increasing the size of the sulfonamide led to a decrease in yield.
29
30 Only traces of product was detected when dichloromethane (Table 1, entry 2)
31 was used as solvent. While performing the reaction in THF provided the desired
32 product in moderate yield, the diastereoselectivity of the transformation was
33 low. Significant background of reaction was observed when either acetone or
34 chloroform was used. The catalyst loading could be drop to 2 mol% without any
35 loss of stereoselectivity, albeit at a lower isolated yield (50 %). Having optimized
36 reaction conditions, experiments to evaluate the substrate scope of this
37 transformation were conducted (Table 2).
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

55 Table 1. Optimization of reaction conditions for the stereoselective Mannich-type reaction ^[a].
56
57
58
59
60




entry	R	solvent	d.r. ^b (<i>anti/syn</i>)	e.r. ^c	yield ^d
1	mesyl	THF	1:1	99:1/99:1	40
2	mesyl	CH ₂ Cl ₂	1:1	Nd ^e	traces
3	mesyl	PhMe	> 19:1	> 99:1	70
4	tosyl	PhMe	5:1	Nd ^e	20
5	mesityl	PhMe	2:1	Nd ^e	15
6 ^f	mesyl	PhMe	> 19:1	> 99:1	55
7 ^g	mesyl	PhMe	-	-	-

34 [a] Reactions were carried out using 0.2 mmol of **1**, 0.006 mmol of (*S*)-TRIP (3 mol%), and 0.21
35 mmol of **2** in PhMe (0.2 M in azlactone). [b] Determined by ¹H NMR analysis of the crude
36 reaction mixture. [c] Determined by enantiodiscriminating HPLC. [d] Isolated yield. [e] Not
37 determined. [f] Without molecular sieves. [g] No catalyst, 48 h.

38
39
40
41
42 Various aromatic imines, containing either electron-withdrawing or electron
43 donating groups, could be used in the reaction. For example, a benzaldehyde
44 derivative containing fluorine at *p*-position works quite well, providing the
45 Mannich adduct **3g** in good yield with both diastereo- and enantioselectivity (>
46 19:1 dr and 98:2 er). Phenylalanine derivative azlactone could also be used
47 under optimized reaction conditions, yielding product **3i** in >98% ee. The
48 relative and absolute stereochemistry (1,2-*anti*) of the Mannich adduct **3b** was
49 determined by X-ray crystallographic structure (Figure 1). The other products
50
51
52
53
54
55
56
57
58
59
60

were assigned on the analogy. To the best of our knowledge this work comprises the first highly enantio- and diastereoselective Mannich-type reaction between azlactone and aldimines catalyzed by a chiral phosphoric acid. A variety of aliphatic imines were evaluated; however, all led to complex product mixtures which could not be deciphered [12].

Table 2. Diastereo- and Enantioselective Mannich-type addition of azlactones to aldimines ^[a].



[a] Reactions were carried out using 0.2 mmol of **1**, 0.006 mmol of (S)-TRIP (3 mol%), and 0.21 mmol of **2** in PhMe (0.2 M in azlactone). [b] Determined by ¹H NMR analysis of the crude reaction mixture. [c] Determined by chiral HPLC. [d] (R)-TRIP used as catalyst. [e] Relative and absolute stereochemistry of **3b** was determined by X-ray crystallography and the other products were assigned in analogy. [f] Only the major diastereomer was isolated. [g] 5 mol% of catalyst.




Figure 1. X-ray crystallographic structure of **3b**.

Yamanaka and Akiyama have proposed that the Mannich-type reaction of a special hydroxyaldimine catalyzed by a chiral phosphoric acid proceeds through coordination of both oxygen atoms of the chiral phosphoric acid to the aldimine. [13] Terada and co-workers have showed a chiral phosphoric acid catalyzed enantioselective addition of azlactones to 3-vinylindoles; in this case, the chiral phosphoric acid activates both the enol intermediate of azlactone and the vinyl double bond system. [14] Thus, a plausible transition state for the reaction of imine and azlactone in the presence of TRIP is proposed. [15] We hypothesize that the phosphoric acid could stabilize the enol intermediate of azlactone and also activated the imine through protonation of the nitrogen lone pair, providing the Mannich adducts in high selectivities (Figure 2).






Figure 2. Plausible activation mode for the stereoselective reaction between azlactones and aldimines catalyzed by a phosphoric acid.

To probe the reversibility of the reaction the enantioenriched Mannich addition product **3b** was resubjected to catalytic reaction condition in the presence of a racemic acid, (+/-)-CSA (camphorsulfonic acid), following the general procedure for Mannich reaction. After 24 h at room temperature, the product was re-isolated in > 99% ee, suggesting that the σ C-C bond step formation is irreversible (eq 1).



The ring opening, followed by amide deprotection of the enantioenriched Mannich addition product **3b** under the presence of a mineral acid provided the amino acid **5** in two steps and with 75 % overall yield (Scheme 1).

Scheme 1. Preparation of amino acid **5**.

Conclusion

In summary, a Brønsted acid catalyzed highly diastereo- and enantioselective Mannich-type addition of azlactones with aldimines is presented. Only 3 mol% of the commercial available phosphoric acid (TRIP) was used to provide protected 1,2-*anti* diamino acid derivatives in moderate to good yields and with near perfect control of both diastereo- and enantioselectivity (up to > 19:1 dr and > 99:1 er). Besides the new σ C-C bond formation, two stereogenic centers are created, one of them a quaternary.

Experimental Section

Representative experimental for the enantio- and diastereoselective Mannich-type addition of azlactones to aldimines: In a flamed screw cap vial and under nitrogen atmosphere and with molecular sieves (50 mg), 0.2 mmol of azlactone was added. After, toluene was added at the concentration of 0.2 mol.L⁻¹ in azlactone. To this solution, 0.006 mmol (3 mol%) of phosphoric acid was added followed by 0.21 mmol of imine. The reaction was kept at room temperature and under nitrogen atmosphere for 24 h. The reaction was then diluted in CH₂Cl₂ (10 mL) and washed with saturated solution of sodium bicarbonate (5 mL). The organic phase was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. An aliquot was taken to the NMR and the diastereoisomeric ratio was measured by ¹H NMR analysis. After, the crude reaction mixture was

1
2
3 purified through silica gel chromatography by using ethyl acetate: hexanes as
4
5 solvents (up to 2:1 ethyl acetate/hexanes). The major diastereomers were
6
7 submitted to chiral HPLC analysis and then fully characterized by the
8
9 conventional elemental analysis.
10

11
12 Characterization data for the Mannich adducts **3a-j**
13

14
15 (**3a**): Diastereoisomeric ratio (dr) from ^1H NMR analysis of crude reaction mixture ($> 19:1$)
16
17 (*anti/syn*). The product was purified by column chromatography on silica gel (Hexanes/AcOEt
18
19 3:1 to 2:1) to afford product **3a** (50.1 mg, 70%); ^1H NMR (250 MHz, CDCl_3) δ : 7.86 (d, 2H, $J =$
20
21 7.1 Hz), 7.58-7.55 (m, 1H), 7.49-7.43 (m, 2H), 7.22-7.19 (m, 5H), 5.71 (d, 1H, $J = 10$ Hz), 4.87
22
23 (d, 1H, $J = 10$ Hz), 2.56 (s, 3H), 1.82 (s, 3H); ^{13}C NMR (63 MHz) δ : 177.5, 161.5, 135.5, 133.1,
24
25 129.1, 128.8, 128.7, 128.0, 127.6, 125.1, 73.7, 61.9, 41.9, 22.1; HRMS: calcd for
26
27 $[\text{C}_{18}\text{H}_{18}\text{N}_2\text{O}_4\text{S}]^+$ ($[\text{M}+\text{H}]^+$): m/z 359.1066, found 359.1079; HPLC Chiralpak IA column
28
29 (Hex/iPrOH 95/05, 0.7 mL/min) tR 26.6 min (major), 28.7 min (minor): $> 99:1$ er. See reference
30
31 4.
32

33
34 (**3b**): Diastereoisomeric ratio (dr) from ^1H NMR analysis of crude reaction mixture ($> 19:1$)
35
36 (*anti/syn*). The product was purified by column chromatography on silica gel (Hexanes/AcOEt
37
38 3:1 to 2:1) to afford product **3b** (51.6 mg, 72%); ^1H NMR (250 MHz, CDCl_3) and ^{13}C NMR (63
39
40 MHz): identical **3a**; HPLC Chiralpak IA column (Hex/iPrOH 95/05, 0.7 mL/min) tR 26.8 min
41
42 (minor), 29.3 min (major): $> 99:1$ er. See reference 4.
43

44
45 (**3c**): Diastereoisomeric ratio (dr) from ^1H NMR analysis of crude reaction mixture ($> 19:1$)
46
47 (*anti/syn*). The product was purified by column chromatography on silica gel (Hexanes/AcOEt
48
49 3:1 to 2:1) to afford product **3c** (57.2 mg, 73%); ^1H NMR (250 MHz, CDCl_3) δ : 7.88-7.85 (m, 2H),
50
51 7.60-7.45 (m, 3H), 7.26-7.14 (m, 4H), 5.75 (d, 1H $J = 9.8$ Hz), 4.86 (d, 1H, $J = 9.8$ Hz), 2.61 (s,
52
53 3H), 1.63 (s, 3H). ^{13}C NMR (75 MHz) δ : 177.5, 162.0, 135.4, 134.6, 133.6, 129.4, 129.3, 128.3,
54
55 125.1, 78.8, 61.5, 42.4, 22.4.; HRMS: calcd for $[\text{C}_{18}\text{H}_{17}\text{N}_2\text{O}_4\text{SCl}]^+$ ($[\text{M}+\text{H}]^+$): m/z 393.0676,
56
57 found 393.0707; HPLC Chiralpak IA column (Hex/iPrOH 90/10, 0.5 mL/min) tR 26.0 min (major),
58
59 30.4 min (minor): 99:1 er.
60

1
2
3 (3d): Diastereoisomeric ratio (dr) from ^1H NMR analysis of crude reaction mixture (10:1)
4 (*anti/syn*). The product was purified by column chromatography on silica gel (Hexanes/AcOEt
5 3:1 to 2:1) to afford product **3d** (56.5 mg, 72%); ^1H NMR (250 MHz, CDCl_3) δ : 7.85-7.57 (m, 2H),
6 7.56-7.26 (m, 3H), 7.22-7.12 (m, 5H), 5.70 (d, 1H, $J = 9.8$ Hz), 4.85 (d, 1H, $J = 9.9$ Hz), 2.64 (s,
7 3H), 1.81 (s, 3H); ^{13}C NMR (75 MHz) δ : 177.4, 162.0, 138.0, 135.0, 133.6, 130.3, 129.6, 129.2,
8 128.2, 128.1, 126.0, 125.1, 73.7, 61.6, 42.4, 22.3; HRMS: calcd for $[\text{C}_{18}\text{H}_{17}\text{N}_2\text{O}_4\text{SCl}]^+$ ($[\text{M}+\text{H}]^+$):
9 m/z 393.0676, found 393.0677; HPLC Chiralpak IA column (Hex/iPrOH 90/10, 0.5 mL/min) tR
10 19.6 min (major), 22.4 min (minor): 96:4 er.

11
12
13
14
15
16
17
18 (3e): Diastereoisomeric ratio (dr) from ^1H NMR analysis of crude reaction mixture (> 19:1)
19 (*anti/syn*). The product was purified by column chromatography on silica gel (Hexanes/AcOEt
20 3:1 to 2:1) to afford product **3e** (39.9 mg, 51%); ^1H NMR (300 MHz, CDCl_3) δ : 8.05 (d, 1H, $J =$
21 7.8 Hz), 7.67-7.62 (m, 2H), 7.56-7.32 (m, 5H), 5.60 (d, 1H, $J = 11.1$ Hz), 5.27 (d, 1H, $J = 11.1$
22 Hz), 2.66 (s, 3H), 1.40 (s, 3H); ^{13}C NMR (75 MHz) δ : 179.4, 162.4, 135.1, 134.5, 133.7, 130.3,
23 130.1, 129.2, 129.0, 128.5, 128.0, 125.5, 73.7, 57.3, 41.5, 21.0; HRMS: calcd for
24 $[\text{C}_{18}\text{H}_{17}\text{N}_2\text{O}_4\text{SCl}]^+$ ($[\text{M}+\text{H}]^+$): m/z 393.0676, found 393.0681; HPLC Chiralpak IA column
25 (Hex/iPrOH 96/04, 0.45 mL/min) tR 59.4 min (major), 67.9 min (minor): 91:9 er.

26
27
28
29
30
31
32
33
34 (3f): Diastereoisomeric ratio (dr) from ^1H NMR analysis of crude reaction mixture (> 19:1)
35 (*anti/syn*). The product was purified by column chromatography on silica gel (Hexanes/AcOEt
36 3:1 to 2:1) to afford product **3f** (64.5 mg, 74%); ^1H NMR (300 MHz, CDCl_3) δ : 7.90-7.87 (m, 2H) ,
37 7.66-7.60 (m, 1H), 7.53-7.48 (m, 2H), 7.41-7.37 (m, 2H), 7.12-7.10 (m, 2H), 5.67 (d, 1H, $J =$
38 9.9 Hz), 4.86 (d, 1H, $J = 9.9$ Hz), 2.63 (s, 3H), 1.82 (s, 3H); ^{13}C NMR (75 MHz) δ : 177.5, 162.0,
39 135.1, 133.6, 132.2, 129.5, 129.2, 128.3, 125.1, 123.7, 73.7, 61.5, 42.5, 22.5; HRMS: calcd
40 for $[\text{C}_{18}\text{H}_{17}\text{N}_2\text{O}_4\text{SBr}]^+$ ($[\text{M}+\text{H}]^+$): m/z 437.0171, found 437.0181; HPLC Chiralpak IB column
41 (Hex/iPrOH 97/03, 0.8 mL/min) tR 44.9 min (major), 54.3 min (minor): 98:2 er.

42
43
44
45
46
47
48
49
50 (3g): Diastereoisomeric ratio (dr) from ^1H NMR analysis of crude reaction mixture (> 19:1)
51 (*anti/syn*). The product was purified by column chromatography on silica gel (Hexanes/AcOEt
52 3:1 to 2:1) to afford product **3g** (55.6 mg, 74%); ^1H NMR (300 MHz, CDCl_3) δ : 7.90-7.88 (m, 2H),
53 7.65-7.60 (m, 1H), 7.52-7.47 (m, 2H), 7.28-7.22 (m, 2H), 6.98-6.92 (m, 2H), 5.93 (d, 1H, $J =$
54 9.9 Hz), 4.90 (d, 1H, $J = 9.9$ Hz), 2.63 (s, 3H), 1.83 (s, 3H); ^{13}C NMR (75 MHz) δ : 177.6, 163.4
55
56
57
58
59
60

(d, $J = 207$ Hz), 162.0, 161.5, 133.6, 131.9, 131.8, 129.8, 129.7, 129.2, 128.3, 125.1, 116.1 (d, $J = 22$ Hz), 74.0, 61.5, 42.3, 22.3; HRMS: calcd for $[C_{18}H_{17}N_2O_4SF]^+$ ($[M+H]^+$): m/z 377.0971, found 377.0991; HPLC Chiralpak IB column (Hex/iPrOH 97/03, 0.8 mL/min) tR 38.4 min (major), 47.4 min (minor): 98:2 er.

(**3h**): Diastereoisomeric ratio (dr) from 1H NMR analysis of crude reaction mixture ($> 19:1$) (*anti/syn*). The product was purified by column chromatography on silica gel (Hexanes/AcOEt 3:1 to 2:1) to afford product **3h** (55.4 mg, 65%): 1H NMR (500 MHz, $CDCl_3$): δ 7.89-7.87 (m, 2H), 7.64-7.61 (m, 1H), 7.54-7.49 (m, 4H), 7.39-7.37 (m, 2H), 5.86 (d, 1H, $J = 9.8$ Hz), 4.98 (d, 1H, $J = 9.8$ Hz), 2.67 (s, 3H), 1.85 (s, 3H). ^{13}C NMR (125 MHz): 177.2, 161.8, 133.5, 131.3 (q, $J = 32.7$ Hz), 129.0, 128.1, 128.0, 125.7 (q, $J = 3.8$ Hz), 123.6 (q, $J = 270.6$ Hz), 73.5, 61.4, 42.3, 22.3. HRMS: calcd for $[C_{19}H_{17}N_2O_4SF_3]^+$ ($[M+H]^+$): m/z 427.0939, found 427.0951; HPLC Chiralpak IB column (Hex/iPrOH 97/03, 0.8 mL/min) tR 41.8 min (major), 52.2 min (minor): 88:12 er.

(**3i**): Diastereoisomeric ratio (dr) from 1H NMR analysis of crude reaction mixture (11:1) (*anti/syn*). The product was purified by column chromatography on silica gel (Hexanes/AcOEt 3:1) to afford product **3i** (57.3 mg, 66 %): 1H NMR (500 MHz, $CDCl_3$): δ 7.70-7.68 (m, 2H), 7.56-7.53 (m, 1H), 7.44-7.40 (m, 2H), 7.29-7.26 (m, 5H), 7.17-7.12 (m, 5H), 5.82 (d, 1H, $J = 10.0$ Hz), 5.06 (d, 1H, $J = 10.0$ Hz), 3.85 (d, 1H, $J = 13.2$ Hz), 3.43 (d, 1H, $J = 13.2$ Hz), 2.58 (s, 3H). ^{13}C NMR (125 MHz) δ : 176.1, 161.7, 133.5, 133.0, 130.3, 129.2, 128.9, 128.7, 128.2, 127.80, 127.75, 127.3, 124.9, 78.8, 61.7, 42.0, 41.7.; HRMS: calcd for $[C_{24}H_{22}N_2O_4S]^+$ ($[M+H]^+$): m/z 435.1379, found 435.1385; HPLC Chiralpak IA column (Hex/iPrOH 95/05, 0.5 mL/min) tR 38.8 min (major), 45.8 min (minor): $> 99:1$ er.

(**3j**): Diastereoisomeric ratio (dr) from 1H NMR analysis of crude reaction mixture ($> 19:1$) (*anti/syn*). The product was purified by column chromatography on silica gel (Hexanes/AcOEt 3:1) to afford product **3i** (47.5 mg, 54 %): 1H NMR (300 MHz, $CDCl_3$): δ 7.91-7.87 (m, 2H), 7.64-7.58 (m, 1H), 7.51-7.46 (m, 2H), 7.11-7.02 (m, 4H), 5.74 (d, 1H, $J = 10.0$ Hz), 4.84 (d, 1H, $J = 10.0$ Hz), 2.56 (s, 3H), 2.25 (s, 3H), 1.83 (s, 3H). ^{13}C NMR (75 MHz) δ : 177.8, 161.7, 139.2, 133.3, 132.8, 129.7, 129.1, 128.2, 127.7, 125.4, 74.0, 61.9, 42.2, 22.4, 21.3.; HRMS: calcd for

[C₁₉H₂₀N₂O₄S]⁺ ([M+H]⁺): *m/z* 373.1222, found 373.1240; HPLC Chiralpak IA column (Hex/iPrOH 95/05, 0.5 mL/min) tR 41.1 min (minor), 53.4 min (major): > 99:1 er.

Procedure for azlactone opening/amide deprotection of Mannich adduct **3b**

To a solution of **3b** (35.0 mg, 0.098 mmol) in 2 mL of CH₃CN was added HCl (12 mol L⁻¹, 0.04 mL, 0.56 mmol). The mixture was stirred for 1h at rt, then the volatile materials were removed under reduced pressure to give the intermediate **4**. To the crude, 2 mL of *conc.* HCl was added and the reaction was stirred at 100 °C for 10 h. The resulting mixture was concentrated under reduced pressure, diluted with water (5 mL) and washed three times with ethyl acetate (3 mL each one). The amino acid **5** (22.5 mg, 0.072 mmol) was obtained by purification through Amberlite IR 120 resin (HCl) in 75 % yield.

(**4**): ¹H NMR (500 MHz, CD₃OD): δ 8.06 (d, 1H, *J* = 10.0 Hz), 7.94 (br, 1H), 7.68-7.66 (m, 2H), 7.56-7.53 (m, 1H), 7.49-7.45 (m, 4H), 7.35-7.32 (m, 2H), 7.30-7.27 (m, 1H), 5.06 (d, 1H, *J* = 9.5 Hz), 2.60 (s, 3H), 1.53 (s, 3H). ¹³C NMR (125 MHz, CD₃OD): 172.8, 166.6, 138.0, 134.1, 131.6, 128.4, 128.2, 128.0, 127.8, 127.1, 62.5, 61.2, 41.3, 19.5. HRMS: calcd for [C₁₈H₂₀N₂O₅S]⁺ ([M+Na]⁺): *m/z* 399.0991, found 399.0982.

(**5**): ¹H NMR (500 MHz, D₂O): δ 7.50-7.46 (m, 5H), 2.68 (s, 3H), 1.53 (s, 3H). ¹³C NMR (125 MHz, D₂O + Dioxane): 173.4, 135.7, 131.8, 131.3, 130.4, 74.2, 64.1, 42.6, 20.8. HRMS: calcd for [C₁₁H₁₇ClN₂O₄S]⁺ ([M-Cl]⁺): *m/z* 273.0909, found 273.0897.

Acknowledgments

We are grateful to FAPEMIG, CAPES, CNPq (305489/2012-7), UFJF and Rede Mineira de Química for the financial support and LabCri (Departamento de Física – Universidade Federal de Minas Gerais) for use of their X-ray facilities. We thank Prof. F. Dean Toste (UC-Berkeley-USA), Prof. Fernando Coelho (IQ-UNICAMP), Prof. Luiz C. Dias (IQ-UNICAMP), Prof. Ronaldo A. Pilli (IQ-UNICAMP), Prof. Adão A. Sabino (DQ-UFMG) and Prof. Mauro V. de Almeida (DQ-UFJF) for all their helps with chemicals and elemental analysis. Prof.

1
2
3 Marco Antônio Barbosa Ferreira (DQ-UFSCar) is also acknowledge for the
4 discussion around the manuscript. G.W.A. thanks Dr. Z. Jane Wang for the
5 comments and English grammar revision.
6
7
8
9

10 **Supporting Information** Copies of NMR spectra, HPLCs as well as X-ray
11 crystallographic details (CCDC 1005467 contains the supplementary
12 crystallographic data for this paper. These data can be obtained free of charge
13 from The Cambridge Crystallographic Data Centre via
14 www.ccdc.cam.ac.uk/data_request/cif.) This material is available free of charge
15 via the Internet at <http://pubs.acs.org>.
16
17
18
19
20
21
22
23

24 **References and Notes**

- 25
26
27 [1] Viso, A.; De la Pradilla, R. F.; García, A.; Flores, A. *Chem. Rev.* **2005**, *105*, 3167.
28
29
30 [2] For a recent use of azlactones as substrates in asymmetric catalysis, see: (a) Esteban, F.;
31 Alfaro, R.; Yuste, F.; Parra, A.; Ruano, J. L. G.; Alemán, J. *Eur. J. Org. Chem.* **2014**, 1395. (b)
32 Qiao, B.; Liu, X.; Duan, S.; Yan, L.; Jiang, Z. *Org. Lett.* **2014**, *16*, 672. (c) Trost, B. M.;
33 Czabaniuk, L. C. *Chem. Eur. J.* **2013**, *19*, 15210. (d) Sun, W.; Zhu, G.; Wu, C.; Li, G.; Hong, L.;
34 Wang, R. *Angew. Chem., Int. Ed.* **2013**, *52*, 8633. (e) Uraguchi, D.; Ueki, Y.; Sugiyama, A.; Ooi,
35 T. *Chem. Sci.* **2013**, *4*, 1308. (f) Oh, J.-S.; Lee, J.-W.; Ryu, T. H.; Lee, J. H.; Song, C. E. *Org.*
36 *Biomol. Chem.* **2012**, *10*, 1052. (g) Lu, G.; Birman, V. B. *Org. Lett.* **2011**, *13*, 356. (h) Han, Z.-Y.;
37 Guo, R.; Wang, P.-S.; Chen, D.-F.; Xiao, H.; Gong, L.-Z. *Tetrahedron Lett.* **2011**, *52*, 5963. (i)
38 De, C. K.; Mittal, N.; Seidel, D. *J. Am. Chem. Soc.* **2011**, *133*, 16802. (j) Dong, S.; Liu, X.; Chen,
39 X.; Mei, F.; Zhang, Y.; Gao, B.; Lin, L.; Feng, X. *J. Am. Chem. Soc.* **2010**, *132*, 10650. (k) Jiang,
40 H.; Paixão, M. W.; Monge, D.; Jørgensen, K. A. *J. Am. Chem. Soc.* **2010**, *132*, 2775. (l) Alba,
41 A.-N. R.; Companyó, X.; Valero, G.; Moyano, A.; Rios, R. *Chem. Eur. J.* **2010**, *16*, 5354. (m)
42 Alba, A.-N. R.; Valero, G.; Calbet, T.; Font-Bardía, M.; Moyano, A.; Rios, R. *Chem. Eur. J.* **2010**,
43 *16*, 9884. (n) Terada, M.; Tanaka, H.; Sorimachi, K. *J. Am. Chem. Soc.* **2009**, *131*, 3430. (o)
44 Uraguchi, D.; Ueki, Y.; Ooi, T. *Science* **2009**, *326*, 120. (p) Uraguchi, D.; Asai, Y.; Ooi, T.
45 *Angew. Chem., Int. Ed.* **2009**, *48*, 733. (q) Jiang, J.; Qing, J.; Gong, L.-Z. *Chem. Eur. J.* **2009**,
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 15, 7031. (r) Cabrera, S.; Reyes, E.; Alemán, J.; Milelli, A.; Kobbelgaard, S.; Jørgensen, K. A. *J.*
4 *Am. Chem. Soc.* **2008**, *130*, 12031. (s) Alemán, J.; Milelli, A.; Cabrera, S.; Reyes, E.;
5 Jørgensen, K. A. *Chem. Eur. J.* **2008**, *14*, 10958.
6
7

8
9 [3] For recent literature on chiral Brønsted acid catalyzed Mannich-type reaction, see: (a)
10 Bhadury, P. S.; Sun, Z. *Curr. Org. Chem.* **2014**, *18*, 127. (b) Jing, C. C.; Xing, D.; Qian, Y., Hu,
11 W. H. *Synthesis*, **2014**, *46*, 1348. (c) Parmar, D.; Sugiono, E.; Raja, S.; Rueping, M. *Chem. Rev.*
12 **2014**, *114*, 9047. (d) Saito, K.; Horiguchi, K.; Shibata, Y.; Yamanaka, M., Akiyama, T. *Chem.*
13 *Eur. J.* **2014**, *20*, 7616. (e) Lv, F. P.; Liu, S. Y.; Hu, W. H. *Asian J. Org. Chem.* **2013**, *2*, 824. (f)
14 Saito, K.; Shibata, Y.; Yamanaka, M.; Akiyama, T. *J. Am. Chem. Soc.* **2013**, *135*, 11740. (g)
15 Wang, Q. G.; Leutzsch, M.; van Gemmeren, M.; List, B. *J. Am. Chem. Soc.* **2013**, *135*, 15334.
16 (h) Zhang, H.; Wen, X. J.; Gan, L. H.; Peng, Y. G. *Org. Lett.* **2012**, *14*, 2126. (i) Peng, F.-Z.;
17 Shao, Z.-H.; *Curr. Org. Chem.* **2011**, *15*, 4144. (j) Terada, M. *Curr. Org. Chem.* **2011**, *15*, 2227.
18 (k) Li, G.; Kaplan, M. J.; Wojtas, L.; Antilla, J. C. *Org. Lett.* **2010**, *12*, 1960. (l) Terada, M.
19 *Synthesis* **2010**, *12*, 1929. (m) Sickert, M.; Abels, F.; Lang, M.; Sieler, J.; Birkemeyer, C.;
20 Schneider, C. *Chem. Eur. J.* **2010**, *16*, 2806.
21
22

23
24 [4] Melhado, A. D.; Amarante, G. W.; Wang, Z. J.; Luparia, M.; Toste, F. D. *J. Am. Chem.*
25 *Soc.* **2011**, *133*, 3517.
26
27

28
29 [5] (a) Liu, X.; Deng, L.; Jiang, X.; Yan, W.; Liu, C.; Wang, R. *Org. Lett.* **2010**, *12*, 876. (b)
30 Uruguchi, D.; Ueki, Y.; Ooi, T. *J. Am. Chem. Soc.* **2008**, *130*, 14088. For a similar example, see:
31 (c) Uruguchi, D.; Koshimoto, K.; Ooi, T. *Chem. Commun.* **2010**, *46*, 300. (d) Zhang, W.-Q.;
32 Cheng, L.-F.; Yu, J.; Gong, L.-Z. *Angew. Chem., Int. Ed.* **2012**, *51*, 4085.
33
34

35
36 [6] Uruguchi, D.; Terada, M. *J. Am. Chem. Soc.* **2004**, *126*, 5356.
37
38

39
40 [7] Akiyama, T.; Itoh, J.; Yokota, K.; Fuchibe, K. *Angew. Chem. Int. Ed.* **2004**, *43*, 1566.
41
42

43
44 [8] (a) Rueping, M.; Kuenkel, A.; Atodiresei, I. *Chem. Soc. Rev.* **2011**, *40*, 4539. (b)
45 Fleischmann, M.; Drettwan, D.; Sugiono, E.; Rueping, M.; Gschwind, R. M. *Angew. Chem. Int.*
46 *Ed.* **2011**, *50*, 6364. (c) Rueping, M.; Nachtsheim, B. J.; leawsuwan, W.; Atodiresei, I. *Angew.*
47 *Chem. Int. Ed.* **2011**, *50*, 6706. (d) Giacalone, F.; Gruttadauria, M.; Agrigento, P.; Noto, R.
48 *Chem. Soc. Rev.* **2012**, *41*, 2406. (e) Phipps, R. J.; Hamilton, G. L.; Toste, F. D. *Nat. Chem.*
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **2012**, 4, 603. (f) Wang, Q.; Leutzsch, M.; Gemmeren, M. V.; List, B. *J. Am. Chem. Soc.* **2013**,
4
5 135, 15334. (g) Mahlau, M.; List, B. *Angew. Chem. Int. Ed.* **2013**, 52, 518.

6
7 [9] (a) Amarante, G. W.; Coelho, F. *Quím. Nova* **2009**, 32, 469. (b) Ávila, E. P.; Amarante, G. W.
8
9 *ChemCatChem* **2012**, 4, 1713. (c) Ávila, E. P.; de Mello, A. C.; Diniz, R.; Amarante, G. W. *Eur.*
10
11 *J. Org. Chem.* **2013**, 1881. (d) Pereira, A. A.; de Castro, P. P.; de Mello, A. C.; Ferreira, B. R.
12
13 V.; Eberlin, M. N.; Amarante, G. W. *Tetrahedron*, **2014**, 70, 3271.

14
15 [10] Klusmann, M.; Ratjen, L.; Hoffmann, S.; Wakchaure, V.; Goddard, R.; List, B. *Synlett*,
16
17 **2010**, 2189.

18
19 [11] Protic solvents could not be adopted, such as methanol or ethanol, because it was
20
21 observed azlactone ring opening as a by product, see reference 9d.

22
23 [12] Different aliphatic tosyl aldimines were synthesized and the desired product was not
24
25 observed under our optimized reaction condition. Several reaction conditions were tested in
26
27 order to prepare mesyl aliphatic aldimines, however, all failed.

28
29 [13] Yamanaka, M.; Itoh, J.; Fuchibe, K.; Akiyama, T. *J. Am. Chem. Soc.* **2007**, 129, 6756.

30
31 [14] Terada, M.; Moriya, K.; Kanomata, K.; Sorimachi, K. *Angew. Chem. Int. Ed.* **2011**, 50,
32
33 12586.

34
35 [15] (a) Simón, L.; Goodman, J. M. *J. Org. Chem.* **2011**, 76, 1775. (b) Terada, M.; Komuro, T.;
36
37 Toda, Y.; Korenaga, T. *J. Am. Chem. Soc.* **2014**, 136, 7044.